AU2007267121A1 - Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases - Google Patents

Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases Download PDF

Info

Publication number
AU2007267121A1
AU2007267121A1 AU2007267121A AU2007267121A AU2007267121A1 AU 2007267121 A1 AU2007267121 A1 AU 2007267121A1 AU 2007267121 A AU2007267121 A AU 2007267121A AU 2007267121 A AU2007267121 A AU 2007267121A AU 2007267121 A1 AU2007267121 A1 AU 2007267121A1
Authority
AU
Australia
Prior art keywords
triazolo
pyrazin
substituted
pyrazol
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007267121A
Other languages
English (en)
Inventor
Martin James Inglis Andrews
Gregory Bar
Mark Stuart Chambers
Juha Andrew Clase
Paul Edwards
Kim Louise Hirst
Angus Macleod
Wolfgang Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of AU2007267121A1 publication Critical patent/AU2007267121A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007267121A 2006-05-31 2007-05-30 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases Abandoned AU2007267121A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US80355206P 2006-05-31 2006-05-31
US60/803,552 2006-05-31
US93176407P 2007-05-25 2007-05-25
US93184407P 2007-05-25 2007-05-25
US93176307P 2007-05-25 2007-05-25
US60/931,844 2007-05-25
US60/931,763 2007-05-25
US60/931,764 2007-05-25
US93210007P 2007-05-29 2007-05-29
US60/932,100 2007-05-29
PCT/EP2007/055246 WO2007138072A2 (en) 2006-05-31 2007-05-30 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases

Publications (1)

Publication Number Publication Date
AU2007267121A1 true AU2007267121A1 (en) 2007-12-06

Family

ID=38618932

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007267121A Abandoned AU2007267121A1 (en) 2006-05-31 2007-05-30 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases

Country Status (20)

Country Link
US (3) US7501411B2 (enExample)
JP (1) JP2009538877A (enExample)
KR (1) KR20090026288A (enExample)
AT (1) ATE465164T1 (enExample)
AU (1) AU2007267121A1 (enExample)
BR (1) BRPI0712531A2 (enExample)
CA (1) CA2653506A1 (enExample)
CR (1) CR10458A (enExample)
DE (1) DE602007006010D1 (enExample)
DK (1) DK2029602T3 (enExample)
EA (1) EA200870592A1 (enExample)
EC (1) ECSP088923A (enExample)
HR (1) HRP20100378T1 (enExample)
IL (1) IL195033A0 (enExample)
MX (1) MX2008015057A (enExample)
NI (1) NI200800299A (enExample)
NO (1) NO20084703L (enExample)
NZ (1) NZ573015A (enExample)
PT (1) PT2029602E (enExample)
WO (1) WO2007138072A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
AU2007267121A1 (en) * 2006-05-31 2007-12-06 Galapagos N.V. Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
US7977352B2 (en) 2006-12-01 2011-07-12 Galapagos Nv Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
WO2008138843A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
CL2009001064A1 (es) 2008-05-07 2009-10-09 Galapagos Nv Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide.
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
TW201120043A (en) * 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
LT3008062T (lt) 2013-06-11 2017-06-12 Bayer Pharma Aktiengesellschaft Pakeistųjų triazolpiridinų provaistų dariniai
JP6435323B2 (ja) * 2013-06-19 2018-12-05 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための新規化合物及びその医薬組成物
US10273226B2 (en) 2014-01-03 2019-04-30 Bayer Animal Health Gmbh Pyrazolyl-heteroarylamides as pesticides
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EP3323809A4 (en) 2015-06-22 2019-01-02 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic amide derivative
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
MY199046A (en) 2016-07-12 2023-10-11 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
SG11201906209SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Bicyclic compounds as allosteric shp2 inhibitors
AU2018210196B2 (en) 2017-01-23 2022-06-02 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
CN109206357A (zh) * 2017-07-04 2019-01-15 浙江九洲药业股份有限公司 一种格列齐特中间体的通式化合物及其制备方法和应用
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
CN111212834B (zh) 2017-10-12 2024-01-19 锐新医药公司 作为变构shp2抑制剂的吡啶、吡嗪和三嗪化合物
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CN108379583B (zh) * 2018-03-27 2021-08-17 北京大学 一种肿瘤转移药物治疗的靶标及其应用
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114945598B (zh) * 2020-02-27 2023-12-01 世延生医股份有限公司 基质金属蛋白酶1的单克隆抗体、其检测试剂盒及其检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
CZ20021210A3 (cs) 1999-10-08 2002-08-14 Grünenthal GmbH Bicyklické deriváty imidazo-3-yl-aminu, způsob jejich výroby, jejich pouľití a léčiva tyto látky obsahující
WO2001027118A2 (de) 1999-10-08 2001-04-19 Grünenthal GmbH Bicyclische imidazo-5-yl-aminderivate
SK286450B6 (sk) 1999-10-08 2008-10-07 Grnenthal Gmbh Bicyklické imidazo-3-yl-amíny, spôsob ich výroby,ich použitie a liečivá obsahujúce tieto látky
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
NO20003636A (no) 2000-07-14 2001-11-26 Zopa As Fremgangsmåte og anordning for kjøling av produkter i et transportsystem
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
IL164703A0 (en) * 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
TW200413378A (en) * 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
ATE525377T1 (de) * 2003-10-15 2011-10-15 Osi Pharm Inc Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
ATE424208T1 (de) 2004-06-09 2009-03-15 Oncalis Ag Proteinkinaseinhibitoren
WO2006049339A1 (ja) 2004-11-08 2006-05-11 Banyu Pharmaceutical Co., Ltd. 新規縮環イミダゾール誘導体
NZ555681A (en) 2004-11-10 2009-08-28 Cgi Pharmaceuticals Inc Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US20060149535A1 (en) * 2004-12-30 2006-07-06 Lg Electronics Inc. Method for controlling speed of audio signals
WO2006086545A2 (en) 2005-02-08 2006-08-17 Robert W Desimone Method to identify novel therapeutics
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
EP1945216A1 (en) 2005-11-10 2008-07-23 Schering Corporation Methods for inhibiting protein kinases
WO2007058942A2 (en) 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
CA2632227A1 (en) 2005-12-01 2007-06-07 Elan Pharmaceuticals, Inc. 5-(arylsulfonyl)-pyrazolopiperidines
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
AU2007267121A1 (en) * 2006-05-31 2007-12-06 Galapagos N.V. Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors

Also Published As

Publication number Publication date
NI200800299A (es) 2010-05-25
US7501411B2 (en) 2009-03-10
US20080090818A1 (en) 2008-04-17
NZ573015A (en) 2010-11-26
DE602007006010D1 (de) 2010-06-02
IL195033A0 (en) 2009-08-03
ECSP088923A (es) 2009-01-30
EA200870592A1 (ru) 2009-08-28
JP2009538877A (ja) 2009-11-12
NO20084703L (no) 2009-02-19
US20100298300A1 (en) 2010-11-25
MX2008015057A (es) 2008-12-10
HRP20100378T1 (hr) 2010-08-31
WO2007138072A3 (en) 2008-02-14
BRPI0712531A2 (pt) 2012-12-25
ATE465164T1 (de) 2010-05-15
WO2007138072A2 (en) 2007-12-06
US7915256B2 (en) 2011-03-29
CR10458A (es) 2009-02-26
KR20090026288A (ko) 2009-03-12
PT2029602E (pt) 2010-07-08
CA2653506A1 (en) 2007-12-06
DK2029602T3 (da) 2010-08-09
US20110178067A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
AU2007267121A1 (en) Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
EP2027124B1 (en) Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
AU2020202707B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
US9006237B2 (en) Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US8138193B2 (en) Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
MXPA06013250A (es) Inhibidores de quinasa como agentes terapeuticos.
JP2013536863A (ja) ピリジノン／ピラジノン、その作製方法、および使用方法
CN108137600A (zh) 作为激酶抑制剂的稠合的吡唑衍生物
US8012983B2 (en) Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases
CN107690434B (zh) 作为tnf活性调节剂的稠合三环咪唑并吡嗪衍生物
CN101454326A (zh) 用于治疗变性和炎性疾病的三唑并吡嗪化合物
EP2029602B1 (en) Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
ES2345066T3 (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias.
HK1128685A (en) Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
RS51372B (sr) Jedinjenja triazolopirazina korisna za tretman degenerativnih upalnih bolesti

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted